Orthofix Medical, Inc. (OFIX)

Over the past six months, Orthofix Medical, Inc.'s stock (OFIX) has experienced several events and analyst actions. In February 2026, the company reported its fourth-quarter and full-year 2025 financial results and provided full-year 2026 financial guidance. In March 2026, Stifel maintained a "Buy" rating but lowered its price target, and Wall Street Zen upgraded Orthofix Medical from a "hold" to a "buy" rating. In April 2026, Orthofix reported preliminary unaudited first-quarter 2026 net sales and announced a strategic realignment of its Spine leadership. Barrington Research reiterated an "Outperform" rating, Canaccord Genuity Group maintained a "Buy" rating but lowered its price target, TD Cowen initiated coverage with a "Hold" rating in January 2026, and Weiss Ratings reissued a "sell" rating in January 2026. The stock price as of April 1, 2026, was $11.61 per share, representing a decline of 28.77% from April 2, 2025.

While specific detailed information on the demand seasonality for Orthofix Medical, Inc.'s products and services is not explicitly provided, Seeking Alpha does track "OFIX Seasonality", suggesting that some level of seasonality in the business is recognized. In the medical device sector, demand can sometimes be influenced by factors such as patient deductibles, holiday schedules affecting elective surgeries, and budgeting cycles of healthcare providers.

Orthofix Medical, Inc. is a global medical technology company specializing in orthopedic and spinal solutions, operating within the Medical Appliances & Equipment industry. The company's core business is divided into two primary segments: Global Spine and Global Limb Reconstruction (Orthopedics). The Global Spine segment includes bone growth therapies, spinal implants, biologics, and enabling technologies like the 7D FLASH™ Navigation System. The Global Limb Reconstruction segment includes products for fracture fixation, external fixation systems, trauma care, sports medicine, limb deformity correction, limb lengthening, and limb preservation, incorporating digital technologies.

Orthofix Medical, Inc. has a global presence with its own sales force and distribution capabilities in key markets, including North America, Europe, Latin America, and Asia Pacific. Its primary offices are located in Lewisville, Texas (headquarters), Carlsbad, California, and Verona, Italy. Additional facilities and offices are located in Irvine, California; Toronto, Canada; Sunnyvale, California; Maidenhead, UK; Munich, Germany; Paris, France; and São Paulo, Brazil.

Orthofix Medical maintains its brand reputation through its focus on innovation, clinical education, and evidence-based practices, partnering with surgeons, research institutions, and patient advocacy groups. The company actively participates in medical conferences and engages in community involvement. Product milestones, such as FDA 510(k) clearance and CE Mark for new systems, also contribute to their reputation in the medical community.

Institutional investors are the dominant force in Orthofix Medical's ownership structure, collectively holding a substantial 54% of the company's shares. Major institutional shareholders include Engine Capital Management, LP, Rubric Capital Management LP, Juniper Investment Company, LLC, Paradigm Capital Management Inc/ny, BlackRock, Inc., Armistice Capital, Llc, Vanguard Group Inc, Millennium Management Llc, Philosophy Capital Management LLC, and Dimensional Fund Advisors Lp. Insiders collectively own 25.88% of Orthofix Medical, and the general public accounts for an 11% stake in the company.